BDX · NYQ · Healthcare
Becton, Dickinson and Company
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 100.48
Market price
USD 180.94
Implied upside
-44.5%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 22.9bn | USD 24.1bn | USD 25.3bn | USD 26.5bn | USD 27.9bn | +5.0% |
| EBIT | USD 3.1bn | USD 3.2bn | USD 3.4bn | USD 3.5bn | USD 3.7bn | +5.0% |
| NOPAT | USD 2.8bn | USD 2.9bn | USD 3.1bn | USD 3.2bn | USD 3.4bn | +5.0% |
| Add depreciation & amortisation | USD 2.6bn | USD 2.8bn | USD 2.9bn | USD 3.1bn | USD 3.2bn | +5.0% |
| Less capital expenditure | USD -2.6bn | USD -2.8bn | USD -2.9bn | USD -3.1bn | USD -3.2bn | +5.0% |
| Less increase in working capital | USD -524.9m | USD -551.1m | USD -578.6m | USD -607.5m | USD -637.8m | +5.0% |
| Free cashflow to firm | USD 2.2bn | USD 2.4bn | USD 2.5bn | USD 2.6bn | USD 2.7bn | +5.0% |
| Discount factor | 0.9672 | 0.9047 | 0.8463 | 0.7917 | 0.7405 | - |
| Present value | USD 2.2bn | USD 2.1bn | USD 2.1bn | USD 2.1bn | USD 2.0bn | -1.8% |
| Present Value Of The Forecast | USD 10.5bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.515 | Reported 0.276, pulled toward 1.0 (Blume) |
| Cost of equity | 7.83% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 49.3bn | 72.0% of capital |
| Total debt | USD 19.2bn | 28.0% of capital, book value as a proxy |
| Tax rate | 9.5% | Effective, capped at statutory |
| WACC | 6.90% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
78% of EV
- Forecast FCFF, final year
- USD 2.7bn
- Capex at depreciation, working capital in reinvestment
- USD 3.4bn
- Less reinvestment at g/ROIC (36.2% of NOPAT)
- USD -1.2bn
- Capitalised
- USD 2.1bn
- ROIC (WACC floor)
- 6.9%
- Terminal value, undiscounted
- USD 50.0bn
- Terminal value, discounted
- USD 37.0bn
- Enterprise value
- USD 47.5bn
- Less net debt
- USD 18.5bn
- Equity value
- USD 29.0bn
Exit at 12.4x EBITDA
86% of EV
- Terminal value, undiscounted
- USD 86.4bn
- Terminal value, discounted
- USD 64.0bn
- Enterprise value
- USD 74.5bn
- Less net debt
- USD 18.5bn
- Equity value
- USD 56.0bn
Spread between methods: 64%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 4.90% | 178.24 | 184.64 | 193.36 | 206.20 | 227.58 |
| 5.90% | 128.04 | 128.81 | 129.57 | 130.33 | 131.10 |
| 6.90% | 99.23 | 99.86 | 100.48 | 101.11 | 101.73 |
| 7.90% | 77.77 | 78.29 | 78.82 | 79.34 | 79.87 |
| 8.90% | 61.17 | 61.62 | 62.07 | 62.51 | 62.96 |
Outlined: this model. Green text: above today's price of 180.94. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 5.0% | 16.8% | +11.8pp |
| EBIT margin | 13.4% | 19.6% | +6.2pp |
| Discount rate | 6.9% | 5.0% | -1.9pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.